Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.

TSX:TH - Post by User

Theratechnologies Inc > New Corporate Presentation up

<< Previous

Bullboard Posts

Next >>

Comment by qwerty22on Mar 16, 2022 12:16pm

68 Views

Post# 34518692

RE:New Corporate Presentation up

I think it's much clearer about what has happened so far in the trial (so much less presuming).

So if they get to patient 18 then maximum we have 14 evaluable patients at a dose of 300+, I guess we have to expect more dropouts. That seems reasonable.

SPCEO1 wrote: https://www.theratech.com/static-files/ddb819a0-33ef-485d-aae8-d587b8cb36bf

I don't think it tells us anything we did not already know or presume but have only had time to glance at it.

<< Previous

Bullboard Posts

Next >>

Increasing summer travel could see these airline stocks soar